Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.eris.co.in | |
Market Cap | 11,356.32 Cr. | |
Enterprise Value(EV) | 11,966.81 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 28.41 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 29.39 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.46 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 184.74 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 4.52 | Calculated using Price: 834.85 |
Dividend Yield | 0.88 | Period Ending 2023-03 |
No. of Shares Subscribed | 13.60 Cr. | 136,028,280 Shares |
FaceValue | 1 | |
About Eris Lifesciences Ltd. | ||
The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders. |
1 Day |
|
-0.74% |
1 Week |
|
-0.43% |
1 Month |
|
-4.24% |
3 Month |
|
-8.39% |
6 Month |
|
+1.24% |
1 Year |
|
+46.49% |
2 Year |
|
+17.53% |
5 Year |
|
+31.07% |
10 Year |
|
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 40.3 | 47.68 | 56.9 | 41.3 | 28.96 | 24.28 | 24.78 | 23.33 | 18.25 | |
Return on Capital Employed (%) | 49.25 | 54.56 | 62.56 | 35.76 | 26.54 | 25.44 | 27.6 | 25.29 | 17.31 | |
Return on Assets (%) | 28.59 | 36.17 | 43.89 | 27.31 | 20.02 | 20.33 | 22.62 | 21.27 | 13.4 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 266 | 300 | 567 | 861 | 1,151 | 1,296 | 1,576 | 1,908 | 2,196 | 2,412 | |
Non Curr. Liab. | 19 | 20 | 12 | 248 | -66 | -80 | -109 | -79 | 729 | 655 | |
Curr. Liab. | 65 | 69 | 129 | 294 | 377 | 220 | 235 | 283 | 521 | 497 | |
Minority Int. | 4 | 3 | 24 | 25 | 18 | 0 | 25 | 16 | |||
Equity & Liab. | 354 | 392 | 732 | 1,428 | 1,481 | 1,437 | 1,703 | 2,113 | 3,471 | 3,580 | |
Non Curr. Assets | 191 | 169 | 463 | 1,061 | 827 | 902 | 1,167 | 1,402 | 2,629 | 2,619 | |
Curr. Assets | 163 | 222 | 270 | 367 | 653 | 535 | 536 | 711 | 843 | 961 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 354 | 392 | 732 | 1,428 | 1,481 | 1,437 | 1,703 | 2,113 | 3,471 | 3,580 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 546 | 597 | 750 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 1,861 | |
Other Income | 3 | 3 | 25 | 26 | 32 | 16 | 9 | 26 | 11 | 10 | |
Total Income | 549 | 600 | 775 | 882 | 1,014 | 1,090 | 1,221 | 1,373 | 1,696 | 1,871 | |
Total Expenditure | -424 | -425 | -480 | -533 | -637 | -706 | -781 | -862 | -1,148 | -1,216 | |
PBIDT | 125 | 175 | 294 | 349 | 377 | 384 | 439 | 511 | 548 | 655 | |
Interest | 0 | 0 | -1 | -11 | -23 | -2 | -2 | -4 | -26 | -61 | |
Depreciation | -16 | -20 | -23 | -26 | -36 | -50 | -43 | -65 | -117 | -164 | |
Taxation | -20 | -20 | -24 | -17 | -26 | -35 | -39 | -36 | -30 | -52 | |
Exceptional Items | |||||||||||
PAT | 89 | 135 | 247 | 295 | 291 | 297 | 355 | 406 | 374 | 379 | |
Minority Interest | 0 | -1 | 0 | -1 | 0 | 0 | 0 | 8 | 8 | ||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 89 | 134 | 247 | 294 | 291 | 297 | 355 | 406 | 382 | 386 | |
Adjusted EPS | 6 | 10 | 18 | 21 | 21 | 22 | 26 | 30 | 28 | 28 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 90 | 90 | 131 | 200 | 235 | 223 | 271 | 375 | 378 | 292 | |
Cash Fr. Inv. | -83 | -92 | -44 | -184 | -590 | -5 | 123 | -323 | -320 | -982 | |
Cash Fr. Finan. | -2 | 0 | -84 | -24 | 363 | -221 | -335 | -82 | -45 | 688 | |
Net Change | 5 | -2 | 4 | -8 | 8 | -3 | 60 | -30 | 14 | -2 | |
Cash & Cash Eqvt | 7 | 5 | 9 | 2 | 11 | 8 | 67 | 37 | 51 | 56 |
Thu, 28 Mar 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING |
Wed, 27 Mar 2024
Closure of Trading Window Closure of Trading Window |
Thu, 21 Mar 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome TRANSCRIPT OF ANALYST AND INVESTOR CALL |
Thu, 28 Mar 2024 |
Higher Delivery Quantity |
Higher Trade Quantity |
Higher Trade and Delivery Quantity |
Close Within 52 Week High Zone |
Close Below Last Month Low |